

Ref. No.: CIAN/BSE/2025-26/15

Sunday, February 01, 2026

To,
The Manager-Listing,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400 001

Ref: BSE Scrip Code: 542678

Symbol: CHCL

ISIN: INE05BN01019

Subject: Outcome of the meeting (CIAN/RPIC/2025-26/06) of the Resolution Plan Implementation Committee ("Implementation Committee") held on Sunday, February 01, 2026, by Cian Healthcare Limited ("Company").

- Reference:**
- i) Disclosures made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), read with Schedule III Part A, Para A thereof, by the Company;
 - ii) Disclosure dated December 19, 2025, in relation to the approval of the resolution plan by the Hon'ble National Company Law Tribunal, Bench-VI, Mumbai ("NCLT") vide its order dated December 18, 2025 ("NCLT Order"), as submitted by the Successful Resolution Applicant ("SRA"), namely Mr. Pradeep Kumar Jain under the relevant provisions of the Insolvency and Bankruptcy Code, 2016 ("Code"); and
 - iii) Disclosure dated November 18, 2025, in relation to the approval of the Audited Consolidated Financial Statements of the Company for the half year and year ended on March 31, 2025.

Dear Sir/Madam,

In compliance with the relevant provisions of Regulation 30 read with Part A, Para A of Schedule III, along with such other applicable provisions of the Listing Regulations, SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024 ("**SEBI Circulars**"), and in accordance with the relevant provisions of the Code, NCLT Order and other applicable laws and regulations, and in reference to the captioned subject, the Company hereby informs that the Implementation Committee, in its physical meeting held today, i.e Sunday, February 01, 2026,



which commenced at 06:00 P.M. (IST) and concluded at 07:18 P.M. (IST), *inter-alia* considered, noted and approved the following matters:

i) Audited Consolidated Financial Results for the half year and year ended on March 31, 2025:

Audited consolidated financial results of the Company, for the half year and year ended on March 31, 2025, the Statement of Assets & Liabilities as on March 31, 2025 and the Statement of Cash Flows for the half year and year ended on March 31, 2025 ("**Consolidated Financial Results**"), along with the Modified Auditor's Report issued by M/s. S S R C A & Co., Chartered Accountants, Statutory Auditors of the Company and the Statement on Impact of Audit Qualifications.

ii) Dissolution of Resolution Plan Implementation Committee ("RPIC") Meeting, consequent to the handover of all the records, assets and information, pursuant to the NCLT Order read with the approved resolution plan:

- a) The total consideration amounting to INR 37,30,13,553 (Indian Rupees Thirty-Seven Crores Thirty Lakhs Thirteen Thousand Five Hundred Fifty-Three Only) ("**Total Bid Value**") has been duly received in the designated escrow account of the Company within the stipulated timelines as specified in the approved resolution plan, and consequently been utilised towards the settlement of Insolvency Resolution Process Cost and all the claims of Financial Creditors, Operational Creditors, Workmen and Employees, and any other eligible claimants (collectively referred to as "**Stakeholders**"), in accordance with the terms of the approved resolution plan read with NCLT Order;
- b) The Interim Board which was constituted pursuant to the meeting of the Implementation Committee (CIAN/RPIC/2025-26/02) held on January 09, 2026, remained devoid of powers pursuant to the provisions of the resolution plan read with NCLT Order during the Resolution Plan Implementation Period being the period commencing from December 18, 2025 (Date of the NCLT Order) up to February 01, 2026 (Resolution Plan Closure Date), as defined under the resolution plan approved by the Hon'ble NCLT. Consequent to the payment of the Total Bid Value, the Implementation Committee stands dissolved. Further, all the powers vested in the Implementation Committee, shall stand conferred upon the Interim Board with effect from conclusion of this meeting, which shall *inter-alia*, include all the powers exercisable in accordance with the provisions of the Companies Act, 2013, the Listing Regulations, and such other applicable laws and relevant provisions of regulation(s), rule(s), master circular(s) and circular(s); and
- c) The Implementation Committee further authorised Mr. Roshen Chordiya, Chairman of the Implementation Committee, to file the requisite closure and/or compliance report before the Hon'ble NCLT, as may be required.

The above-stated audited consolidated financial results are also being submitted in XBRL mode.



The outcome will also be hosted on the website of the Company at www.cian.co

Kindly take the above submission on record and oblige.

Thanking you.

For **Cian Healthcare Limited**



ROSHEN CHORDIYA

Chairman of the Resolution Plan Implementation Committee
(Erstwhile Resolution Professional of Cian Healthcare Limited)
IBBI Registration No.: IBBI/PA-001/IP-P-02840/2023-2024/14347
(Email For Correspondence: cirp.cianhealthcare@gmail.com,
Address: 114, Solaris Hubtown, N. S. Phadke Marg,
Near East West Flyover, Andheri (E), Mumbai-400069)
Place: Pune



Independent Auditor's Report on the Consolidated Financial Results of CIAN Healthcare Limited for Half Year and Year ended March 31, 2025 pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, 2016)

To,
**The Chairman,
Resolution Plan Implementation Committee,
Cian Healthcare Limited,
(A Company formerly under Corporate Insolvency Resolution Process pursuant to NCLT order dated 11 June 2024).**

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we refer to the audited half-yearly consolidated financial results of the Company for the period ended **31 March 2025**, approved on **11 June 2025**, on which a **Disclaimer of Conclusion** was issued by the auditors due to non-availability of requisite financial information of the Company and its subsidiary.

At the time of approval of the aforesaid consolidated financial results, the financial information of **Dr. Smith's Biotech Private Limited**, a subsidiary of the Company, was not available and, therefore, could not be considered for the purpose of consolidation.

Subsequently, the limited reviewed interim financial information of the subsidiary, reviewed by another auditor and dated **31 January 2026**, has been received by the Company. Accordingly, based on the availability of such financial information, the consolidated financial results for the period ended **31st March 2025** have been prepared to include the financial results of the subsidiary and consolidated financial results have been approved by the Authorised authority of the Company and have been subjected to a limited review by the statutory auditors.

Background

The Hon'ble National Company Law Tribunal, Mumbai Bench ("NCLT") admitted an insolvency petition filed by an operational creditor against Cian Healthcare Limited ("the Company") and ordered commencement of the Corporate Insolvency Resolution Process ("CIRP") vide its order dated 11 June 2024, appointing Mr. Roshen Chordiya as the Interim Resolution Professional. Subsequently, the insolvency petition was withdrawn vide order dated 20 June 2024, and thereafter the order for commencement of CIRP was restored with effect from 14 August 2024.

The Committee of Creditors ("CoC"), at its meeting held on 21 February 2025, approved the appointment of Mr. Roshen Chordiya as the Resolution Professional under Section 22(2) of the Insolvency and Bankruptcy Code, 2016 ("IBC"), which was confirmed by the Hon'ble NCLT vide its order dated 20 March 2025.

Subsequently, the Hon'ble NCLT, Mumbai Bench, vide its order dated 18 December 2025, approved the Resolution Plan and concluded the CIRP of the Company. Pursuant to the said order,

the Resolution Plan has become binding on the Company and all stakeholders in accordance with the provisions of the IBC.

Pursuant to approval of the Resolution Plan and conclusion of the CIRP, a Resolution Plan Implementation Committee has been constituted in accordance with the approved Resolution Plan, comprising representatives of the Committee of Creditors, the Successful Resolution Applicant, and the Chairman of the Committee. The implementation of the approved Resolution Plan is presently in progress under the supervision of the said Committee.

Accordingly, the accompanying Statement has been approved and signed by the Chairman of the Resolution Plan Implementation Committee, in exercise of the powers vested under the approved Resolution Plan.

The Consolidated annual financial results includes the financial results of the following entities:

Holding Company

Cian Healthcare Limited

Subsidiary Company

Dr. Smith's Biotech Private Limited

Auditor's Responsibility

Basis of Disclaimer of Conclusion

- a) We draw attention to the fact that the Company has been admitted into the Corporate Insolvency Resolution Process ("CIRP") under the provisions of the Insolvency and Bankruptcy Code, 2016. As informed to us, claims from operational creditors, financial creditors, employees, statutory authorities and other parties, including claims relating to guarantee obligations, have been submitted to the Resolution Professional ("RP"). The determination and reconciliation of the overall obligations and liabilities, including principal and interest on borrowings, are pending and shall be finalized during the CIRP upon approval and implementation of the Resolution Plan by the Adjudicating Authority. Pending such reconciliation and final determination, no accounting impact has been recorded in the audited standalone and consolidated financial results in respect of any excess, short or non-receipt of claims or any modification to existing obligations. Consequently, we are unable to comment on the adjustments, if any, that may be required to these audited financial results arising from the final determination of claims and obligations under the approved Resolution Plan.
- b) Under **Note 3** to the consolidated financial results, management is responsible for assessing the Company's ability to continue as a going concern and for disclosing, as applicable, matters related to going-concern uncertainty. In terms of Section 20 of the Insolvency and Bankruptcy Code, 2016, it is incumbent upon the Resolution Professional (RP) to manage the operations of the Company as a going concern during the Corporate Insolvency Resolution Process (CIRP). Accordingly, these audited consolidated financial results have been prepared on a going-concern basis. The Company has incurred a net loss during the

half-year ended 31st March 2025, its current liabilities exceeds current assets, resulting in negative working capital, and it has defaulted in meeting certain debt and other obligations.

- c) We draw attention to the investment of ₹708.84 lakhs made by the Company in its subsidiary, Dr. Smiths Biotech Private Limited. The Hon'ble National Company Law Tribunal, Mumbai Bench ("NCLT") has admitted an insolvency petition filed by a financial creditor against the said subsidiary and, vide its order dated 28 April 2025, has ordered the commencement of the Corporate Insolvency Resolution Process ("CIRP"). Ms. Megha Agrawal (IBBI/IPA-001/IP-P-01456/2018-2019/12272) has been appointed as the Interim Resolution Professional. As the CIRP is currently in progress, the outcome and recoverability of the investment are presently uncertain. Accordingly, we are unable to comment on any adjustments, if required, to the carrying value of the said investment and the consequential impact, if any, on the Consolidated financial results of the Company for the period under review.
- d) In the absence of a comprehensive review of the carrying amounts of certain assets including long-term loans and advances, balances with government authorities, deposits, trade receivables, other non-current assets, and other current assets and liabilities, as well as non-availability of confirmations for a substantial portion of such balances, we were unable to verify their accuracy and recoverability. Consequently, we are unable to comment on any adjustments, if required, to the carrying amounts of these assets and liabilities and the possible impact thereof on the loss for the period ended 31st March 2025.
- e) In the absence of sufficient and appropriate audit evidence relating to the carrying value of Property, Plant and Equipment and Capital Work-in-Progress as at 31st March 2025, we were unable to verify the accuracy of the amounts reported. Accordingly, we are unable to comment on whether any adjustments are required to the carrying amounts of these assets and the consequential impact, if any, on the consolidated financial results for the half year ended 31st March 2025.
- f) The group have not recognized interest on borrowings during the year. Further, loan confirmations for borrowings amounting to ₹3,311.14 lakhs pertaining to Cian Healthcare Limited were not provided. In absence of sufficient audit evidence, we are unable to verify the completeness, existence, and accuracy of borrowings and related finance costs.
- g) The Company has not been able to provide adequate supporting documentation, records, or reconciliation in respect of inventories as at 31st March 2025. Physical verification of inventories has not been carried out during the half year, and we were not able to satisfy ourselves by alternative means regarding the existence, condition, and valuation of inventories appearing in the audited consolidated financial results. Further, during the year ended 31 March 2025, we had reported that inventories were recorded at ₹2,562.11 lakhs, whereas as per the valuation report provided by the Resolution Professional, the assessed value was ₹1,869.14 lakhs. The difference in valuation had a material impact on the cost of

goods sold and closing inventory. In the absence of complete supporting documentation, physical verification, and reconciliation records, we are unable to comment on the appropriateness of the carrying amount of inventories as presented in these audited Consolidated financial results.

- h) Due to pending confirmations and assessments of refinancing arrangements, loan covenants, and repayment schedules, we are unable to verify the classification of Long-term and Short term Borrowings. As a result, we cannot determine the appropriateness of the classification in accordance with the applicable financial reporting framework.
- i) We note that the sales and purchase figures recorded in the books of account for the half year ended 31st March 2025 do not fully reconcile with the turnover and inward supply figures reported in the corresponding GST returns filed for the same period. The management and the Resolution Professional have represented that the differences primarily arise on account of timing variances, incomplete data capture, and pending reconciliations between the accounting system and the GST portal. The reconciliation of revenue, input tax credits, and outward supplies is provided by the management and the effect of the same on GST returns is in progress and will be finalized in subsequent periods.
- j) We note that the Company has delayed in remitting statutory dues including Provident Fund (PF), Professional Tax (PT), Employees' State Insurance Corporation (ESIC), Tax Deducted at Source (TDS) and other applicable statutory dues to the appropriate authorities within the prescribed time limits. Furthermore, we were unable to verify the balances related to these statutory liabilities as reflected in the books of accounts due to non-availability of sufficient and appropriate audit evidence and supporting documentation. In our opinion and to the best of our information and according to the explanations given to us, the extent of default and the impact on the financial statements could not be determined.
- k) The Company has recognized income from foreign incentives such as Duty Drawback, RODTEP (Remission of Duties and Taxes on Exported Products) benefits, and foreign exchange gain/loss during the year ended 31st March 2025. However, the Company has not provided sufficient and appropriate audit evidence in support of the aforesaid income, including relevant documentation, reconciliations. In the absence of such audit evidence, we are unable to determine the accuracy, completeness, and appropriateness of the income recognized in the financial results. Accordingly, we are unable to determine whether any adjustments might be necessary in respect of such income and the consequential impact, if any, on the profit/loss for the year, reserves, and disclosures in the financial results as at and for the year ended 31st March 2025.

Subsidiary's Financial Results -

The Statement includes the interim financial results of Dr. Smith's Biotech Private Limited, a subsidiary, whose interim financial statements reflect Total Assets of Rs. 1857.54 Lakhs as at 31st March 2025, total revenue of Rs.(4.58) lakhs & net cash outflows of Rs. (2.81) lakhs

as at 31st March 2025 as considered in the Statement. The financial statements of this subsidiary for the half year ended 31st March 2025 have been audited/Reviewed by another statutory auditor and the audit/Review report contains a qualified opinion, which has been furnished to us and relied upon for the purpose of consolidation.

Our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the report of the subsidiary's statutory auditor. However, since we have not independently reviewed or audited the financial statements of the subsidiary, we are unable to comment on the accuracy, completeness, or the impact of the matters forming part of the qualification on the accompanying consolidated financial results.

The qualification of the subsidiary's auditor is primarily on account of material uncertainty relating to going concern due to cessation of operations and ongoing CIRP, lack of verifiable evidence for inventory existence and valuation, non-confirmation and recoverability concerns relating to trade receivables, inability to verify trade payables, absence of a fixed asset register and physical verification of fixed assets, unreconciled GST input tax credit balances, continued recognition of deferred tax assets despite lack of virtual certainty, Company not maintained or provide monthly/quarterly financials breakdowns or Trial Balances and review of general ledgers revealed a significant volume of journal entries and adjustment recorded as of March 31, 2025.

Accordingly, our conclusion on the Statement is not modified in respect of the above matter.

Auditor's responsibilities for the audit of the Consolidated Financial results

Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error; design and perform audit procedures responsive to those risks; and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Group has adequate internal financial controls system in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management / RP.
- Conclude on the appropriateness of respective management's / RP's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The consolidated financial results include the results for the half year ended 31 March 2025, being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year-to-date figures up to the half year ended 30 September of the relevant financial year, which were subject to limited review by us, as required under the Listing Regulations. Our opinion on the audit of the consolidated financial results for the year ended 31 March, 2024 is not modified in respect of this matter.

For SSRCA & Co
Chartered Accountants
Firm Registration No.: 108726W

CA Hemant Samdani
Partner
Membership No.: 155955
UDIN: 26155955FOZBMW1674
Place : Pune
Date : 01/02/2026



ANNEXURE-I

Statement of Impact of Audit Qualifications (for audit report with modified opinion) submitted along- with Annual Audited Consolidated-financial Results of CIAN Healthcare Limited for the Financial Year Ended on 31st March 2025.

Statement of Impact of Audit Qualifications for the Financial Year ended 31 March 2025 [See regulation 33 of SEBI (LODR) (Amendment) Regulations, 2016]				
	Sl. No.	Particulars	Audited Figures (Rs. in Lakhs) (as reported before adjusting for qualifications)	Audited Figures (Rs. in Lakhs) (as reported after adjusting for qualifications)
	1	Turnover/Total Income	3,106.66	3,106.66
	2	Total Expenditure	5706.19	5706.19
	3	Net Profit/(loss) after tax	(2,597.75)	(2,597.75)
	4	Earnings per share (Rs.)	(10.39)	(10.39)
	5	Total Assets	15,605.85	15,605.85
	6	Total Liabilities	12,370.12	12,370.12
	7	Networth	3235.73	3235.73
II	Audit Qualifications: Details of Audit Qualification: Frequency of Qualification: During the year, Disclaimer of Opinion is given.			
	b) Type of Audit Qualification:		Disclaimer Opinion	



	<p>(c) For Audit Qualification(s) where the impact is quantified by the Auditor, Managements Views:</p> <p>The Hon'ble National Company Law Tribunal, Mumbai Bench ("NCLT") admitted an Insolvency and Bankruptcy petition filed by an operational creditor against Cian Healthcare Limited ("the Company") and ordered the commencement of Corporate Insolvency Resolution Process (CIRP) of Cian Healthcare Limited, the Company/Corporate Debtor, vide its Order dated 11th June 2024 and Mr. Roshen Chordiya was appointed as the Interim Resolution Professional by, the NCLT. Further, the Petition was withdrawn by NCLT in order dated 20 June 2024. Thereafter, the order commencement of CIRP was restored from 14th August 2024. The Committee of Creditors ('COC') at its meeting held on 21st February 2025 approved the appointment of Mr. Roshen Chordiya, Interim Resolution Professional as Resolution Professional (IBBI Registration No.: IBBI/IPA-001/IP-P02840/2023-2024/14347) as per Section 22 (2) of Insolvency & Bankruptcy Code, 2016, which has been confirmed by NCLT vide its order dated 20 March 2025, with a direction to initiate appropriate action contemplated, with extant provisions of the Insolvency and Bankruptcy Code, 2016 and other related rules</p> <p>The RP of the view, that after approval of resolution plan by adjudicating authority, the successful PRA would revive the Corporate Debtor, thus the value of inventory and GST balance as per books would be carried at same level.</p>
	<p>(d) For Audit Qualification(s) where the impact is not quantified by the Auditor:</p>
	<p>(i) Management's estimation on the impact of audit qualification: Nil</p>
	<p>(ii) If Management is unable to estimate the impact, reasons for the same:</p>
<p>a) We draw attention to Note 2(e) of the standalone financial results regarding admission of the Company into Corporate Insolvency Resolution Process ("CIRP"), and pending determination of obligations and liabilities with regard to various claims submitted by the operational / financial / other creditors and employees including claims for guarantee obligation and interest payable on loans. We are unable to comment on adjustments, if any, pending reconciliation and determination of final obligation.</p>	<p>a. As given in Report of Resolution Professional. Further, Interlocutory Application for approval of resolution plan is already filed in Honorable NCLT on 23.05.2025, Post approval of Resolution Plan by the Honorable NCLT, any debit or credit, being the balancing figure, will be given effect as per the approved Resolution Plan by the successful resolution applicant.</p>
<p>Frequency of Qualification: During the year, Disclaimer of Opinion is given.</p> <p>b) In the absence of comprehensive review of carrying amount of certain assets (loans and advances, balances with government authorities, deposits, trade receivables, unamortized expenses and other receivables) and liabilities and non-availability of confirmation of substantial balances, we are unable to comment upon adjustments, if any, that may be required to the carrying amount of such assets and liabilities and consequential</p>	<p>b. As given in Report of Resolution Professional. Further, Interlocutory Application for approval of resolution plan is already filed in Honorable NCLT on 23.05.2025, Post approval of Resolution Plan by the Honorable NCLT, any debit or credit, being the balancing figure, will be given effect as per the approved Resolution Plan by the</p>



<p>impact, if any, on the loss for the year ended 31 March 2025..</p> <p>Frequency of Qualification: During the year, Disclaimer of Opinion is given.</p> <p>c) In the absence of sufficient and appropriate audit evidence of the carrying value of Property, Plant and Equipment and Capital Work in Progress as at 31st March 2025, we are unable to comment upon whether any adjustments are required to the carrying amounts of these assets. Consequently, we are also unable to comment on the potential impact of the same on the standalone financial results for the year ended 31st March 2025.</p> <p>D) We have not received loan statements or external confirmations from the banks, financial institutions, or Non-Banking Financial Companies (NBFCs) for the outstanding loan amounting to ₹ 3,311.14 lakhs as at the balance sheet date. Due to the absence of sufficient and appropriate audit evidence regarding the existence and completeness of these loan balances, we are unable to determine whether any adjustments might be necessary to the carrying amounts of borrowings or their related disclosures in the financial results for the year ended 31 March 2025.</p> <p>Frequency of Qualification: During the year, Disclaimer of Opinion is given.</p> <p>e) The Company has recognized income from foreign incentives such as Duty Drawback, RODTEP (Remission of Duties and Taxes on Exported Products) benefits, and foreign exchange gain/loss during the year ended 31 March 2025. However, the Company has not provided sufficient and appropriate audit evidence in support of the aforesaid income, including relevant documentation, reconciliations. In the absence of such audit evidence, we are unable to determine the accuracy, completeness, and appropriateness of the income recognized in the financial results. Accordingly, we are unable to determine whether any adjustments might be necessary in respect of such income and the consequential impact, if any, on the profit/loss for the year, reserves, and disclosures in the financial results as at and for the year ended 31 March 2025.</p>	<p>successful resolution applicant.</p> <p>c. As given in Report of Resolution Professional. Further, Interlocutory Application for approval of resolution plan is already filed in Honorable NCLT on 23.05.2025, Post approval of Resolution Plan by the Honorable NCLT, any debit or credit, being the balancing figure, will be given effect as per the approved Resolution Plan by the successful resolution applicant.</p> <p>d. As given in Report of Resolution Professional. Further, Claim form as received from financial Institution for outstanding as on 14th August 2024 has been provided. Interlocutory Application for approval of resolution plan is already filed in Honorable NCLT on 23.05.2025, Post approval of Resolution Plan by the Honorable NCLT, any debit or credit, being the balancing figure, will be given effect as per the approved Resolution Plan by the successful resolution applicant.</p> <p>e. As given in Report of Resolution Professional. Further, Interlocutory Application for approval of resolution plan is already filed in Honorable NCLT on 23.05.2025, Post approval of Resolution Plan by the Honorable NCLT, any debit or credit, being the balancing figure, will be given effect as per the approved Resolution Plan by the successful resolution applicant.</p>
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



<p>procedures carried out as part of the IBC process are confidential in nature and could not be shared with other than the COC and Hon'ble NCLT. In the opinion of the RP, the matter is highly sensitive, confidential and may have adverse impact on the resolution process. Accordingly, we are unable to comment on the impact, if any, on the accompanying standalone financial results including recognition, measurement and disclosures that may arise had we been provided access to the above-mentioned information.</p>	<p>nature.</p>
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------

<p>Signatories:</p>	<p>iii) Auditors comment on (i) and(ii) above: Auditor's comment are self explanatory in auditor's report.</p>
<p>Roshen Chordiya Chairman of the Resolution Plan Implementation Committee (Erstwhile Resolution Professional of Cian Healthcare Limited) IBBI Registration No.: IBBI/IPA-001/IP-P02840/2023-2024/14347 Email ID: cirp.cianhealthcare@gmail.com Date: 01/02/2026</p>	
<p>Statutory Auditors For S S R CA & Co Firm Registration No. 108726W Hemant Samdani Partner Membership Number - 155955 Date: 01/02/2026</p>	

CIAN HEALTHCARE LIMITED
CIN: L24233PN2003PLC017563

Reg.Add: Office no 301, 3rd Floor, Konark Icon, Mundhwa - Kharadi Road, Kirtane Baugh, Magarpatta, Hadapsar, Pune, Maharashtra, India, 411028.
Registered Email ID : cs@clan.co

Consolidated Audited Financial Results for the Half year and year ended on March 31, 2025

(Rs. in Lakh)

Particulars	Half year ended		Year Ended	Year Ended
	31/03/2025	30/09/2024	31/03/2025	31/03/2024
A. Date of start of reporting period	01/10/2024	01/04/2024	01/04/2024	01/04/2023
B. Date of end of reporting period	31/03/2025	30/09/2024	31/03/2025	31/03/2024
C. Whether results are audited or unaudited	(Audited)	(Unaudited)	(Audited)	(Audited)
CONTINUING OPERATIONS				
I. Revenue from operations	1,190.30	1,889.54	3,079.84	6,169.55
II. Other Income	19.92	6.90	26.82	44.07
III. Total Income (I+II)	1,210.22	1,896.44	3,106.66	6,213.62
IV. Expenses				
Cost of materials consumed	22.46	900.19	922.65	3,714.04
Purchases of Trading Goods	205.12	202.48	407.60	398.36
Changes in Inventories of finished goods, work-in-progress	856.50	81.61	938.11	-1,037.86
Other Operating Expenses	91.13	243.26	334.39	559.79
Employee benefits expenses	295.14	405.48	700.62	856.88
Finance costs	50.63	240.91	291.54	578.96
Depreciation and amortisation expense	195.63	243.49	439.12	546.66
Other expenses	247.87	198.92	446.79	591.99
Total expenses	1,964.48	2,516.34	4,480.82	6,208.81
V. Profit / (Loss) before exceptional and extraordinary items and tax (III-IV)	-754.26	-619.90	-1,374.16	4.81
VI. Exceptional Items	20.25	1,205.12	1,225.37	-0.20
VII. Profit / (Loss) before extraordinary items and tax (V-VI)	-774.51	-1,825.02	-2,599.53	5.01
VIII. Extraordinary Items				
Add / (Less) : Prior Period Incomes / (Expenses)	-	-	-	0.20
IX. Profit / (Loss) before Tax (VII-VIII)	-774.51	-1,825.02	-2,599.53	5.21
X. Tax expenses/ (credit)				
(a) Current tax expense for current year - MAT	-	-	-	0.79
(b) Tax expense relating to prior years	-3.87	-	-3.87	-18.93
(c) Deferred tax	2.10	-	2.10	-61.51
Total Tax Expense	-1.77	-	-1.77	-79.65
XI. Net profit / (Loss) for the period/year after tax (XII-XIII)	-772.73	-1,825.02	-2,597.75	84.86
XII. Other comprehensive Income (including tax effect)				
Items that will not be reclassified to profit or loss (Net of tax) in subsequent period	-	-	-	-
XIII. Total comprehensive income/ (loss) for the period/year	-772.73	-1,825.02	-2,597.75	84.86
XIV. Paid up equity share capital (Face Value Rs. 10 per share)	2,499.58	2,499.58	2,499.58	2,499.58
XV. Other Equity	-	-	-	-
XVI. Earnings per share (before extra-ordinary and exceptional items)				
Basic	-3.01	-2.48	-5.49	0.34
Diluted	-3.01	-2.48	-5.49	0.34
XVII. Earnings per share (after extra-ordinary and exceptional items)				
Basic	-3.09	-7.30	-10.39	0.34
Diluted	-3.09	-7.30	-10.39	0.34

For Cian Healthcare Limited
CIN: L24233PN2003PLC017563

Roshen Chordiya
Chairman of the Resolution Plan Implementation Committee
(Erstwhile Resolution Professional of Cian Healthcare Limited)
IBBI Reg.No.: IBBI/IPA-001/IP-P02840/2023-2024/14347



Date:- 01/02/2026

Place:- Pune

CIAN HEALTHCARE LIMITED
CIN: L24233PN2003PLC017563

Reg.Add: Office no 301, 3rd Floor, Konark Icon, Mundhwa - Kharadi Road, Magarpatta, Hadapsar, Pune,
Maharashtra, India, 411028. Registered Email ID : cs@cian.co

Consolidated Audited Cash Flows Statement for the year ended 31st March 2025

(Rs. in Lakh)

Particulars	For the year ended	For the year ended
	31 Mar 2025	31 Mar 2024
	Audited	Audited
A. Date of start of reporting period	01/04/2024	01/04/2023
B. Date of end of reporting period	31/03/2025	31/03/2024
Cash Flow from operating activities		
Net Profit after tax	-2,597.75	84.86
Adjustment for:		
- Depreciation and amortization expense	439.12	546.66
- Interest Expenses	250.60	537.96
- Interest & Dividend received	-15.14	-9.86
- Deferred Tax Liability	2.10	-61.51
Operating profit before working capital changes	-1,921.08	1,098.11
Increase / (Decrease) In Trade Payables	1,040.45	417.21
Increase / (Decrease) In Other Current Liabilities	1,757.12	4.21
Increase / (Decrease) In Other Non Current Liabilities	-664.70	139.14
Increase / (Decrease) In Provisions	21.41	-1.96
(Increase) / Decrease In Inventories	1,485.16	-428.37
(Increase) / Decrease In Trade Receivables	309.17	574.79
(Increase) / Decrease In Other Current Assets	-71.72	91.01
(Increase) / Decrease In Other Non Current Asset	93.80	-710.85
(Increase) / Decrease In Short-Term loans and advances	25.60	-6.87
Cash used in operations	2,075.20	1,176.40
Net cash generated from/(used in) operating activities	2,075.20	1,176.40
Cash flow from Investing activities		
Purchase of property, plant and equipment, Intangible assets	-3.88	-16.54
(Increase) / Decrease In Capital Work in Progress	-36.68	-81.32
Interest & Dividend received	15.14	9.86
Proceeds / (Repayment) of Other Financial Assets/Long Term Liabilities	-	-57.65
Net cash used in investing activities	-25.42	-145.65
Cash flow from financing activities		
Proceeds from long term borrowings	-2,063.83	-188.76
Proceeds / (Repayment) from / of short term borrowings	1,993.45	-323.59
Proceeds / (Repayment) for Other Financial Assets	-71.17	-
Interest paid	-250.60	-531.96
Net cash (used in)/generated from financing activities	-392.15	-1,044.30
Increase / (Decrease) in cash and cash equivalents	1,657.63	-13.55
Cash and cash equivalents at beginning of the year	119.41	132.96
Cash and cash equivalents	1,777.04	119.41
Cash In Hand	0.49	6.84
With banks - on current account	1,008.00	10.75
With banks - In Deposits account	768.55	101.82
Cash and cash equivalents as per Balance Sheet	1,777.04	119.41

Notes :

- i) The above Cash flow statement has been prepared under the indirect method set out in Accounting Standard-3, "Cash Flow Statement" notified under section 133 of the Companies Act 2013, read together with paragraph 7 of the Companies (Accounts)
- ii) All figures in brackets/Negative indicate outflow.

For Cian Healthcare Limited
CIN: L24233PN2003PLC017563

Roshen Chordiya
Chairman of the Resolution Plan Implementation Committee
(Erstwhile Resolution Professional of Cian Healthcare Limited)
IBBI Reg.No.: IBBI/IPA-001/IP-P02840/2023-2024/14347



Date:- 01/02/2026
Place:- Pune

CIAN HEALTHCARE LIMITED
CIN: L24233PN2003PLC017563

Reg.Add: Office no 301, 3rd Floor, Konark Icon, Mundhwa - Kharadi Road, Kirtane Baugh, Magarpatta, Hadapsar, Pune,
Maharashtra, India, 411028. Registered Email ID : cs@clan.co


Consolidated Audited Statement of Assets and Liabilities

(Rs. in Lakh)

Particulars	As at	As at	
	31 March 2025	31 March 2024	
	(Audited)	(Audited)	
A. Date of start of reporting period	01/04/2024	01/04/2023	
B. Date of end of reporting period	31/03/2025	31/03/2024	
A	EQUITY AND LIABILITIES		
1	Shareholders' funds		
(a)	Share capital	2,499.58	2,499.58
(b)	Reserves and surplus	736.15	3,333.91
2	Non-current liabilities		
(a)	Long-term borrowings	685.79	2,749.62
(b)	Deferred tax liabilities (net)	53.12	51.01
(c)	Other long-term liabilities	105.61	770.31
(d)	Long-term provisions	76.70	101.97
	Total	4,156.95	9,506.39
3	Current liabilities		
(a)	Short-term borrowings	4,812.96	2,819.51
(b)	Trade payables		
	I) Total outstanding dues of micro enterprises and small enterprise	1,416.83	655.27
	II) Total outstanding dues of creditors other than micro enterprises and small enterprises	2,750.74	2,471.85
(c)	Other current liabilities	2,361.81	604.69
(d)	Short-term provisions	106.56	59.87
	Total	11,448.90	6,611.19
	TOTAL EQUITY AND LIABILITIES	15,605.85	16,117.59
B	ASSETS		
1	Non-current assets		
(a)	Property, Plant and equipment & Intangible Assets		
	(I) Property, Plant and equipment	3,493.16	3,928.40
	(II) In-tangible Assets	-	-
	(III) Capital work-in-progress	1,506.60	1,469.92
(b)	Non-current Investments	488.84	488.84
(c)	Long-term loans and advances	1,198.04	1,126.84
(d)	Other non-current assets	1,835.52	1,929.32
	Total	8,522.15	8,943.32
2	Current assets		
(a)	Inventories	2,607.57	4,092.72
(b)	Trade receivables	1,739.10	2,048.27
(c)	Cash and cash equivalents	1,777.04	119.41
(d)	Short-term loans and advances	532.34	557.93
(e)	Other current assets	427.65	355.93
	Total	7,083.70	7,174.27
	TOTAL ASSETS	15,605.85	16,117.59

For Cian Healthcare Limited
CIN: L24233PN2003PLC017563

Roshen
Roshen Chordiya
Chairman of the Resolution Plan Implementation Committee
(Erstwhile Resolution Professional of Cian Healthcare Limited)
IBBI Reg.No.: IBBI/IPA-001/IP-P02840/2023-2024/14347



Date:- 01/02/2026
Place:- Pune

Notes to the Statement of Audited Consolidated financial results for the year ended 31 March 2025:

1. The Hon'ble National Company Law Tribunal, Mumbai Bench ("NCLT") admitted an Insolvency and Bankruptcy petition filed by an operational creditor against Cian Healthcare Limited ("the Company") and ordered the commencement of Corporate Insolvency Resolution Process (CIRP) of Cian Healthcare Limited, the Company/Corporate Debtor, vide its Order dated 11th June 2024 and Mr. Roshen Chordiya was appointed as the Interim Resolution Professional by, the NCLT. Further, the Petition was withdrawn by NCLT in order dated 20 June 2024. Thereafter, the order commencement of CIRP was restored from 14th August 2024. The Committee of Creditors ('COC') at its meeting held on 21st February 2025 approved the appointment of Mr. Roshen Chordiya, Interim Resolution Professional as Resolution Professional as per Section 22 (2) of Insolvency & Bankruptcy Code, 2016, which has been confirmed by NCLT vide its order dated 20 March 2025, with a direction to initiate appropriate action contemplated, with extant provisions of the Insolvency and Bankruptcy Code, 2016 and other related rules. In view of pendency of the Corporate Insolvency Resolution Process (CIRP), the powers of the Board of Directors of the Company have been suspended, and the management of the affairs of the Company and power of the Board of Directors are now vested with the Resolution Professional, and the Statement is being signed by the Resolution Professional in exercise of such powers.
 - a) Interim Resolution Professional (IRP) had made a first public announcement on 17-Aug-2024 and second announcement on 18-Dec-2024 inviting claims from creditors of the Company. In response to the public announcement, till date Resolution Professional (RP) has received total claims of INR 81,43,20,511/- which comprises of claim for a sum of INR 32,66,83,190/- from secured financial creditors sum of INR 6,90,75,266/- from unsecured financial creditors, INR 6,01,98,350/- from operational creditors (Government Dues), INR 49,02,784/- from Operational creditors (Workmen) ,INR 46,87,249.93/- from Operational creditors (Employees), INR 34,87,38,518/- from operational creditors (other than Workmen and Employees and Government Dues), INR 35,152/- from other creditors. The claim of INR 68,60,76,684/- are admitted, INR 8,97,43,586/- are under Verification, INR 20,85,968/- Amount of Contingent Claims and the remaining claim of INR 8,97,43,586 have been rejected.
2. With respect to the Consolidated financial results for the half year and year ended 31 March 2025, the RP has signed the same solely for the purpose of ensuring compliance by the company with applicable laws, and subject to the following disclaimers:
 - a) The RP has furnished and signed the report in good faith and knowledge; on such information or other legal proceedings, which he marked the RP in terms of Section 20 of the Code;
 - b) No assurance, right, entitlement (whether contract or licenses) or opinion (contract breach status) is extended as a representation or warranty, express or implied, of the RP including job continuance, representations and findings.
 - c) The RP, in review of the Consolidated financial results for the half year and year ended 31 March 2025, has relied upon the directions provided by the directors of the Corporate Debtor, and certifications, representations, and assurances made by the directors of the Corporate Debtor, in relation to these standalone and consolidated financial results. The standalone financial results of the Corporate Debtor for the half year and year ended 31 March 2025 have been relied on solely on the basis of information and data shared by the management, certifications and submissions of the directors of the Corporate Debtor. For all the information and data, the RP

relies on all such information and data as in conformity with the Companies Act, 2013 and other applicable laws with respect to the preparation of the standalone and financial results and that they are true and correct to the view of the directors of the Corporate Debtor as of the dates and period indicated therein. Accordingly, the RP is not making any representation regarding accuracy, veracity or completeness of the same or documents in the standalone and consolidated financial results.

- d) In terms of the Code's provisions, the RP must undertake a process to determine overdue financial transactions.
- e) Considering various issues involving admission of the Corporate Debtor, there are various claims submitted by the operational creditors, the financial creditors including corporate guarantee obligations and other creditors. The overall obligations and liabilities including obligation for interest on loans shall be determined during the CIRP and accounting impact, if any, will be given on completion of CIRP."

3. The Above Financial Results and Statement of Assets and Liabilities were prepared as per Accounting Standards and reviewed by the RP and taken on record at the meeting held on 11th June 2025. The statutory auditors have expressed disclaimer of opinion in respect of the standalone results for the year ended 31 March 2025.

4. The Earning per Share (EPS) has been computed in accordance with the AS-20.

5. List of Subsidiary as on March 31, 2025

Name of the Entity: Dr. Smith's Biotech Private Limited

Relationship: Subsidiary

Country of Incorporation: India

% of Ownership: 100%

6. The Status of Investors Complaints during the half year ended on March 31, 2025, is as under

Pending at the beginning of the above period: NIL

Received during the above period: NIL

Disposed during the above period: NIL

Remaining unsolved at the end of the above period: NIL

7. The company has investment in subsidiary amounting Rs. 708.84 lakhs. However, as the Hon'ble National Company Law Tribunal, Mumbai Bench ("NCLT") admitted an Insolvency and Bankruptcy petition filed by a financial creditor against Dr. Smiths Biotech Private Limited ("the subsidiary") and ordered the commencement of Corporate Insolvency Resolution Process (CIRP) of Dr. Smiths Biotech Private Limited, the Company/Corporate Debtor, vide its Order dated 28th April 2025 and Ms. Megha Agrawal (IBBI/IPA-001/IP-P-01456/2018-2019/12272) is appointed as the Interim Resolution Professional by, the NCLT. As the CIRP is under progress, RP/Management has not considered any impact of carrying value of the investment in subsidiary.

8. The RP/ Management has disclosed the following items as exceptional in nature in the Statement of Statement of Financial Result for the year ended 31st March 2025:

a) Impact of Batch Closures -

The Company has accounted for an amount of ₹1109.01 lakhs pertaining to batch closures relating to the previous financial year. This has been considered exceptional due to its non-recurring nature and significant financial impact on the current year's financial results.

b) Sundry Balances Written Off :

An amount of ₹108.42 lakhs has been written off during the year in respect of sundry balances. These balances were identified as irrecoverable or no longer payable and have been classified as exceptional, considering their materiality and the intent to present a clearer view of the Company's operating performance.

These items have been disclosed separately to comply with the disclosure requirements under Ind AS and to enhance the understanding of users regarding the Company's underlying operational performance. These events are non-recurring and do not relate to the Company's ordinary business activities.

9. Figures for the previous year/Period have been regrouped/reclassified wherever necessary, to make them comparable.

10. The company is primarily engaged in the business of Pharmaceuticals which is a single reportable segment for the half year/ year ended March 31, 2025, hence no separate segment reporting is given as per AS-17.

11. As per MCA Notification dated 16.02.2015, companies whose shares are listed on SME exchange as referred to in Chapter XB of SEBI (Issue of Capital disclosure Requirements) Regulations, 2009 are Exempted from the compulsory requirement of Adoption of IND-AS. Hence, company has prepared its financials as per Accounting Standards.

For Cian Healthcare Limited (in CIRP)

CIN: L24233PN2003PLC017563



Roshen Chordiya

Chairman of the Resolution Plan Implementation Committee

(Erstwhile Resolution Professional of Cian Healthcare Limited)

IBBI Registration No.: IBBI/PA-001/IP-P02840/2023-2024/14347

Email Id: cirp.cianhealthcare@gmail.com